Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

Figures & data

Table 1. Patient demographic and clinical characteristics.

Parameter	Patients (n = 275)
Gender, n (%)
Female	101 (36.7)
Male	174 (63.3)
Age, years ± SD	50.80 ± 14.78
Weight, kg ± SD	77.01 ± 12.98
Height, cm ± SD	171.04 ± 8.21
Mean psoriasis duration, years ± SD	14.20 ± 10.59
Localization, n (%)
Uncommon localizations	82 (29.8)
Palmo-plantar	14 (5.1)
Genital	18 (6.6)
Folds	21 (7.6)
Hair/face	15 (5.6)
Nails	30 (10.9)
Articular involvement, n (%)	67 (24.4)
Mean duration of articular involvement, years ± SD	3.45 ± 4.47
Comorbidities, n (%)	197 (71.6)
Obesity	36/269 (13.4)
Type 2 diabetes	36 (13.1)
Dyslipidemia	71 (25.8)
Hypertension	82 (29.8)
Cardiovascular diseases	23 (8.4)
Psychiatric conditions	21 (7.6)
Autoimmune diseases	18/272 (6.6)
Atopy/allergy	26 (9.5)
Thyroid disease	7 (2.5)
Arthrosis	4 (1.5)
Osteoporosis	4 (1.5)
Benign prostatic hypertrophy	5 (1.8)
Others	57 (20.7)
Concurrent treatment, n (%)	137 (49.8)
Infectious diseases, n (%)	20 (7.3)
HBV+	6 (2.2)
HCV+	9 (3.3)
TBC+	5 (1.8)
Previous treatments, n (%)	229 (83.3)
Acitretin	81 (29.5)
Adalimumab	63 (22.9)
Ciclosporin	164 (59.6)
Certolizumab Pegol	8 (2.9)
Etanercept	43 (15.6)
Phototherapy	72 (26.2)
Golimumab	7 (2.6)
Guselkumab	2 (0.7)
Infliximab	29 (10.6)
Ixekizumab	4 (1.5)
Methotrexate	91 (33.1)
Brodalumab	1 (0.4)
Ustekinumab	31 (11.3)

HBV: hepatitis B virus; HCV: hepatitis C virus; SD: standard deviation; TBC: tuberculosis.

Table 2. Change in Psoriasis Area and Severity Index (PASI) score and body surface area (BSA) over time.

	Parameter, n/n (%)
PASI
	Mild (PASI < 10)	Moderate (10 ≤ PASI < 20)	Severe (PASI ≥ 20)
Baseline (n = 275)	30 (10.9)	90 (32.7)	155 (56.4)
Week 4 (n = 244)	133 (54.5)	103 (42.2)	8 (3.3)
Week 12 (n = 275)	266 (96.7)	8 (2.9)	1 (0.4)
Week 24 (n = 265)	264 (99.6)	0 (0.0)	1 (0.4)
Week 48 (n = 264)	263 (99.6)	1 (0.4)	0 (0.0)
Week 96 (n = 264)	264 (100.0)	0 (0.0)	0 (0.0)
Week 144 (n = 265)	265 (100.0)	0 (0.0)	0 (0.0)
Week 192 (n = 265)	258 (97.4)	7 (2.6)	0 (0.0)
Week 240 (n = 222)	222 (100.0)	0 (0.0)	0 (0.0)
BSA
	Mild (BSA ≤ 3)	Moderate (3 < BSA ≤ 10)	Severe (BSA > 10)
Baseline (n = 265)	0 (0)	25 (9.4)	240 (90.6)
Week 4 (n = 244)	36 (14.8)	153 (62.7)	55 (22.5)
Week 12 (n = 275)	164 (59.6)	97 (35.3)	14 (5.1)
Week 24 (n = 265)	220 (83.0)	41 (15.5)	4 (1.5)
Week 48 (n = 265)	236 (89.1)	26 (9.8)	3 (1.1)
Week 96 (n = 251)	233 (92.8)	18 (7.2)	0 (0.0)
Week 144 (n = 265)	248 (93.6)	15 (5.7)	2 (0.8)
Week 192 (n = 265)	222 (83.8)	31 (11.7)	12 (4.5)
Week 240 (n = 222)	201 (90.5)	10 (4.5)	11 (5.0)

Table 3. Change in Dermatology Life Quality Index (DLQI) over time.

	Effects on patients’ lives, n/n (%)
	No effect (DLQI 0–1)	Small (DLQI 2–5)	Moderate (DLQI 6–10)	Very large (DLQI 11–20)	Extremely large (DLQI 21–30)
Baseline (n = 264)	0 (0.0)	2 (0.8)	9 (3.4)	91 (34.5)	162 (61.4)
Week 4 (n = 238)	29 (12.2)	50 (21.0)	123 (51.7)	36 (15.1)	0 (0.0)
Week 12 (n = 275)	110 (40.0)	106 (38.5)	52 (18.9)	7 (2.5)	0 (0.0)
Week 24 (n = 263)	164 (62.4)	83 (31.6)	16 (6.1)	0 (0.0)	0 (0.0)
Week 48 (n = 264)	215 (81.4)	45 (17.0)	3 (1.1)	1 (0.4)	0 (0.0)
Week 96 (n = 264)	237 (89.8)	24 (9.1)	3 (1.1)	0 (0.0)	0 (0.0)
Week 144 (n = 265)	238 (89.8)	23 (8.7)	4 (1.5)	0 (0.0)	0 (0.0)
Week 192 (n = 265)	208 (78.5)	35 (13.2)	12 (4.5)	10 (3.8)	0 (0.0)
Week 240 (n = 222)	190 (85.6)	19 (8.6)	12 (5.4)	1 (0.4)	0 (0.0)

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.